[1] Vermehren J, Park JS, Jacobson IM, et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol,2018,69:1178-1187.
[2] Wei L, Omata M, Lim YS, et al. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Res,2018,158:178-184.
[3] Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat,2018,37:17-39.
[4] Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based treatment regimens for hepatitis c virus infection: a systematic review and meta-analysis. Hepat Mon,2016,16: e41077.
[5] Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol,2018,69: 293-300.
[6] Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol, 2019,70:1019-1023. |
